Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
HUTCHMED (China) Limited (HCM) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates primarily within the oncology and immunology segments of the pharmaceutical industry, with an emphasis on innovative small-molecule and biologic drugs. Its core revenue drivers are proprietary oncology products approved in Mainland China, alongside milestone payments and royalties from global licensing partnerships.
The company serves patients, hospitals, and healthcare systems, primarily in China, with expanding reach into the United States, Europe, and other international markets through strategic partners. HUTCHMED’s positioning is differentiated by its fully integrated model that combines in-house drug discovery, clinical development, regulatory expertise, and commercial capabilities within China, complemented by global collaborations. The company was founded in 2000 as Chi-Med and later rebranded as HUTCHMED, reflecting its evolution from a traditional pharmaceutical business into an innovation-driven biopharmaceutical enterprise backed by the Hutchison Group.
Business Operations
HUTCHMED generates revenue through two primary operating segments: Oncology/Immunology Drug Development and Commercialization and Other Ventures. The core business focuses on internally discovered or co-developed therapies, including marketed oncology products such as fruquintinib, savolitinib, and sulfatinib, which are commercialized directly in China and, in some cases, licensed internationally. Revenue streams include product sales, upfront payments, development milestones, and royalties from partners.
Operations are supported by in-house research and development centers, manufacturing oversight, and a dedicated commercial sales force in China. Internationally, HUTCHMED relies on collaborations with global pharmaceutical companies for late-stage development and commercialization outside China. The company maintains subsidiaries and operational entities under Hutchison China MediTech Limited, enabling control over R&D, regulatory filings, and post-marketing activities.
Strategic Position & Investments
HUTCHMED’s strategic direction centers on advancing a pipeline of first-in-class and best-in-class oncology therapies while expanding global reach through partnerships. Growth initiatives prioritize late-stage clinical development, regulatory approvals in major markets, and lifecycle management of approved products. The company has entered into significant licensing and co-development agreements, including collaborations involving AstraZeneca PLC, Takeda Pharmaceutical Company Limited, and Eli Lilly and Company, which provide capital, validation, and access to international markets.
Investments are concentrated in precision oncology, kinase inhibitors, and combination therapies, with an increasing focus on global clinical trials. The company does not operate as a diversified holding company; instead, it maintains a focused portfolio of drug candidates and subsidiaries aligned with its biopharmaceutical strategy. Emerging areas of involvement include biomarker-driven therapies and expanded indications for existing oncology assets.
Geographic Footprint
HUTCHMED is headquartered in Hong Kong, with principal operations and commercial activities in Mainland China. The company has established a strong market presence across major Chinese provinces through its oncology sales infrastructure. Research and development activities are conducted in China, with clinical trial programs extending into the United States, Europe, and parts of Asia-Pacific.
International influence is primarily achieved through licensing agreements and global clinical collaborations rather than wholly owned overseas manufacturing or sales operations. Through these partnerships, HUTCHMED’s products and pipeline assets have exposure to regulatory agencies and markets in North America and Europe, supporting its long-term globalization strategy.
Leadership & Governance
HUTCHMED is guided by an experienced leadership team with deep expertise in pharmaceuticals, oncology, and global drug development. The company’s governance reflects a strategic emphasis on scientific rigor, disciplined capital allocation, and long-term value creation through innovation and partnerships.
Key executives include:
- Christian Hogg – Chief Executive Officer
- Michael Shi – Chief Financial Officer
- Junshi Chang – Chief Scientific Officer
- Pierre Beaurang – Chief Medical Officer
- Simon To – Head of Commercial Operations
Leadership philosophy centers on building a globally competitive biopharmaceutical company rooted in China-based innovation, while adhering to international regulatory and governance standards consistent with its listings and reporting obligations.